WVW. M. Monique Verschuren

W. M. Monique Verschuren

*This is an algorithmically generated author record based on publicly available information.

W. M. Monique Verschuren has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • A Blokstra

    National Institute for Public Heath and the Environment, PO Box 1, 37230 BA Bilthoven, The Netherlands

    1 shared publication
  • Angelika de Bree

    Department of Chronic Disease Epidemiology, National Institute of Public Health and the Environment, Bilthoven, Netherlands

    1 shared publication
  • Anne-Lise Bjørke-Monsen

    From the Department of Chronic Disease Epidemiology, National Institute of Public Health and the Environment, Bilthoven, Netherlands (AdB and WMMV); the Laboratory of Pediatrics and Neurology, University Medical Center Nijmegen, Nijmegen, Netherlands (AdB, NMJvdP, SGH, FJMT, and HJB); the Scientific and Technical Institute of Nutrition and Food, U557 INSERM/U1125 INRA/ISTNA-CNAM, Paris (AdB); and the LOCUS for Homocysteine and Related Vitamins, University of Bergen, Bergen, Norway (A-LB-M)

    1 shared publication
  • Astrid C. J. Nooyens

    Centre for Prevention and Health Services Research, National Institute for Public Health and the Environment, Bilthoven, the Netherlands

    1 shared publication
  • Boukje M. van Gelder

    The authors are with the Centre for Prevention and Health Services Research, National Institute for Public Health and the Environment (RIVM), Bilthoven, Netherlands

    1 shared publication
  • Bruggen Monique A.M. Jacobs-Van der

    1 shared publication

Latest Publications

  • The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands

    by Linda Kok, Peter Engelfriet, Bruggen Monique A.M. Jacobs-Van der, Rudolf T. Hoogenveen, Hendriek C. Boshuizen, Monique W.M. Verschuren

    A new Dutch guideline for cardiovascular disease management substantially extends the number of individuals for whom treatment with statins and/or antihypertensive agents is recommended. We estimated the cost-effectiveness of implementing the new guideline at the national level. First, the number of currently untreated individuals who would become eligible for cholesterol-lowering or antihypertensive treatment under the new guideline was estimated using data from a recent population study. Cost-effectiveness of treating this group of patients was then assessed using a mathematical model. Implementing the guideline in the age category 30-69 years would lead to an additional 465,000 individuals requiring treatment. Over a period of 20 years, the cumulative incidence of acute myocardial infarction in the whole population would drop by 3.0%, that of stroke by 3.9%, and all-cause mortality would drop by 0.9%. The lifetime cost-effectiveness ratio was calculated to be 15,000 Euro per quality-adjusted life year gained. In the age categories 70-79 years and 80 years or above, an additional 600,000 and 450,000 persons, respectively, would need to be treated, resulting in corresponding reductions in cumulative incidences of 14 and 18% (acute myocardial infarction), 17 and 22% (stroke), and 1.2 and 0.6% (all-cause mortality) with cost-effectiveness ratios of 20,800 and 32,300 Euro, respectively, per quality-adjusted life year. Complete implementation of the new guideline would lead to a considerable increase in the number of individuals requiring treatment. This would be cost-effective up to the age of 70 years.


  • Smoking and Cognitive Decline Among Middle-Aged Men and Women: The Doetinchem Cohort Study

    by Astrid C. J. Nooyens, Boukje M. van Gelder, W. M. Monique Verschuren

    Objectives. We studied the effect of smoking on cognitive decline over a 5-year period at middle age (43 to 70 years). Methods. In the Doetinchem Cohort Study, 1964 men and women in the Netherlands were examined for cognitive function at baseline and 5 years later. The association between smoking status and memory function, speed of cognitive processes, cognitive flexibility, and global cognitive function were assessed. Results. At baseline, smokers scored lower than never smokers in global cognitive function, speed, and flexibility. At 5-year follow-up, decline among smokers was 1.9 times greater for memory function, 2.4 times greater for cognitive flexibility, and 1.7 times greater for global cognitive function than among never smokers. Among ever smokers, the declines in all cognitive domains were larger with increasing number of pack-years smoked. Conclusions. Interventions to prevent or stop people from smoking may postpone cognitive decline in middle-aged persons.


  • Open Access

    Cohort Profile: The Doetinchem Cohort Study

    by Wmm Verschuren, A Blokstra, Hsj Picavet, H. Smit

    The origin of the Doetinchem Cohort Study lies within the Monitoring Project on Cardiovascular Disease Risk Factors (MP-CVDRF), which was aimed at providing prevalence estimates of cardiovascular disease risk factors, such as smoking, blood pressure and serum cholesterol levels. During 1987–91 each year an age- and sex-stratified random sample of men and women aged 20–59 years, was invited to participate. The MP-CVDRF was carried out in three towns in The Netherlands (Amsterdam in the west, Doetinchem in the east and Maastricht in the south), and from each of the three towns, about 12 000 men and women were examined. In the subsequent Monitoring Project on Chronic Disease Risk Factors (MORGEN-project), carried out from 1993–97, in Doetinchem only respondents from the MP-CVDRF were invited to participate, while in Amsterdam and Maastricht again random samples from the general population were examined. The protocol was extended, because the focus broadened from cardiovascular to other chronic diseases such as cancer, diabetes, musculoskeletal disorders and COPD. Due to extension of the protocol, with similar budget, not all 12 405 participants in the MP-CVDRF could be re-invited. Instead, a random sample of in total 7769 of the respondents at baseline was invited for re-examination. This random sample is considered the basis of the cohort (Figure 1).


  • Open Access

    Effect of the methylenetetrahydrofolate reductase 677C→T mutation on the relations among folate intake and plasma folate and homocysteine concentrations in a general population sample

    by Angelika de Bree, Wm Monique Verschuren, Anne-Lise Bjørke-Monsen, Nathalie Mj van der Put, Sandra G Heil, Frans Jm Trijbels, Henk J Blom

    Background: Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme in folate and homocysteine metabolism. The common MTHFR 677C→T polymorphism decreases the enzyme's activity. Objective: The objective of the study was to assess the effect of the polymorphism on the relations among folate intake, plasma folate concentration, and total plasma homocysteine (tHcy) concentration. Design: The design was a cross-sectional analysis in a random sample (n = 2051) of a Dutch cohort (aged 20–65 y). Results: At a low folate intake (166 μg/d), folate concentrations differed significantly among the genotypes (7.1, 6.2, and 5.4 nmol/L for the CC, CT, and TT genotypes, respectively; P for all comparisons < 0.05). At a high folate intake (250 μg/d), folate concentrations in CT and CC subjects did not differ significantly (8.3 and 8.6 nmol/L, respectively, but were significantly higher (P = 0.2) than those in TT subjects (7.3 nmol/L; P = 0.04). At a low folate concentration (4.6 nmol/L), TT subjects had a significantly higher (P = 0.0001) tHcy concentration than did CC and CT subjects (20.3 compared with 15.0 and 14.1 μmol/L, respectively), whereas at a high folate concentration (11.9 nmol/L), the tHcy concentration did not differ significantly between genotypes (P > 0.2; Conclusions: At any folate intake level, TT subjects have lower plasma folate concentrations than do CT and CC subjects. Yet, at high plasma folate concentrations, tHcy concentrations in TT subjects are as low as those in CT and CC subjects.